ArticleNature communications2026
Clinical attribute-based risk matrix for prognostication in immunotherapy-treated non-small cell lung cancer.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Biomarkers used to guide immunotherapy in non-small cell lung cancer (NSCLC) are invasive, variably available, and insufficient to capture clinical and regional heterogeneity, leaving many patients inadequately stratified for prognosis. We develop a clinical attribute-based framework that leverages routinely collected variables to estimate survival risk, even when baseline data are incomplete. We analyze 17 051 patients with NSCLC treated with immunotherapy, assembled from published cohorts and tertiary centers across multiple regions, and evaluate seventeen common clinical attributes using a two-stage survival modeling strategy with external validation in Western and East Asian populations. Clinical attributes exhibit context-dependent prognostic effects across variable-defined strata and survival endpoints, with performance status and disease stage emerging as the most consistent determinants of survival risk prediction, alongside region-specific modifiers. Here we show that this "start-anywhere" clinical risk matrix provides robust, population-aware prognostic stratification and complements biomarkers for assessing immunotherapy outcomes in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.